Assignee
FIBROGEN INC
US·57 granted patents·61 pending applications·961 citations·filing 1995–2023
Top patents by PatentIndex Score
118 records- 0198US7323475B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2004·Granted Jan 29, 2008·97 cites·46 claims
- 0298US6992172B1Recombinant gelatinsFIBROGEN INC·Filed 2000·Granted Jan 31, 2006·229 cites·47 claims
- 0397US8883823B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2013·Granted Nov 11, 2014·20 cites·52 claims
- 0497US7629357B2Nitrogen-containing heteroaryl compounds and methods of user thereofFIBROGEN INC·Filed 2006·Granted Dec 8, 2009·38 cites·52 claims
- 0596US8017625B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2008·Granted Sep 13, 2011·42 cites·47 claims
- 0696US7863292B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2007·Granted Jan 4, 2011·28 cites·38 claims
- 0795US10626090B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2017·Granted Apr 21, 2020·6 cites·10 claims
- 0895US8765956B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2013·Granted Jul 1, 2014·19 cites·19 claims
- 0995US7928120B2Cyanoisoquinoline compounds and methods of use thereofFIBROGEN INC·Filed 2007·Granted Apr 19, 2011·40 cites·36 claims
- 1095US7696223B2Pyrrolo- and Thiazolo-pyridine compounds, and methods of use thereofFIBROGEN INC·Filed 2007·Granted Apr 13, 2010·54 cites·32 claims
- 1193US10927081B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2018·Granted Feb 23, 2021·3 cites·46 claims
- 1293US10894774B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2017·Granted Jan 19, 2021·3 cites·23 claims
- 1393US10882827B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2018·Granted Jan 5, 2021·3 cites·24 claims
- 1493US9371288B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2014·Granted Jun 21, 2016·7 cites·5 claims
- 1593US7405274B2Connective tissue growth factor antibodiesFIBROGEN INC·Filed 2004·Granted Jul 29, 2008·47 cites·28 claims
- 1692US9920011B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2013·Granted Mar 20, 2018·10 cites·6 claims
- 1792US9695170B2Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylaseFIBROGEN INC·Filed 2016·Granted Jul 4, 2017·5 cites·32 claims
- 1892US9115085B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2013·Granted Aug 25, 2015·12 cites·11 claims
- 1992US7871617B2Antibodies that bind to a portion of the VWC domain of connective tissue growth factorFIBROGEN INC·Filed 2008·Granted Jan 18, 2011·16 cites·45 claims
- 2091US9340511B2Process for making isoquinoline compoundsFIBROGEN INC·Filed 2013·Granted May 17, 2016·16 cites·48 claims
- 2191US9271970B2Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylaseFIBROGEN INC·Filed 2014·Granted Mar 1, 2016·7 cites·30 claims
- 2291US7713986B2Compounds and methods for treatment of chemotherapy-induced anemiaFIBROGEN INC·Filed 2006·Granted May 11, 2010·17 cites·8 claims
- 2390US9339527B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2014·Granted May 17, 2016·7 cites·20 claims
- 2489US11680048B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2020·Granted Jun 20, 2023·1 cites·14 claims
- 2589US11680047B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2020·Granted Jun 20, 2023·1 cites·23 claims
- 2689US9918977B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2016·Granted Mar 20, 2018·3 cites·13 claims
- 2789US7618940B2Fat regulationFIBROGEN INC·Filed 2003·Granted Nov 17, 2009·35 cites·16 claims
- 2889US7393928B2Recombinant gelatinsFIBROGEN INC·Filed 2005·Granted Jul 1, 2008·11 cites·24 claims
- 2988US10272078B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2018·Granted Apr 30, 2019·2 cites·6 claims
- 3088US9617218B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2015·Granted Apr 11, 2017·5 cites·6 claims
- 3188US9387200B2Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activityFIBROGEN INC·Filed 2015·Granted Jul 12, 2016·5 cites·17 claims
- 3288US9174976B2Cyanoisoquinoline compounds and methods of use thereofFIBROGEN INC·Filed 2014·Granted Nov 3, 2015·9 cites·41 claims
- 3387US10092558B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2016·Granted Oct 9, 2018·3 cites·20 claims
- 3487US9708269B2Process for making isoquinoline compoundsFIBROGEN INC·Filed 2016·Granted Jul 18, 2017·6 cites·9 claims
- 3587US2024182424A1Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2023·Application pending·0 cites
- 3685US9000006B2Thienopyridine compounds, and methods of use thereofFIBROGEN INC·Filed 2014·Granted Apr 7, 2015·7 cites·14 claims
- 3784US9149476B2Thiochromene derivatives as HIF hydroxylase inhibitorsFIBROGEN INC·Filed 2014·Granted Oct 6, 2015·7 cites·37 claims
- 3884US2024076364A1Connective tissue growth factor antibodiesFIBROGEN INC·Filed 2022·Application pending·0 cites
- 3982US10118897B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2017·Granted Nov 6, 2018·2 cites·18 claims
- 4081US9631013B2Therapeutic method for pancreatic cancerFIBROGEN INC·Filed 2015·Granted Apr 25, 2017·6 cites·6 claims
- 4180US9643928B2Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acidFIBROGEN INC·Filed 2014·Granted May 9, 2017·4 cites·39 claims
- 4280US9409892B24-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitorsFIBROGEN INC·Filed 2013·Granted Aug 9, 2016·6 cites·30 claims
- 4379US10039515B2Methods for treating idiopathic pulmonary fibrosisFIBROGEN INC·Filed 2016·Granted Aug 7, 2018·3 cites·5 claims
- 4479US2021369702A1Methods for treating anemia in subjects having kidney failure using inhibitors of hypoxia-inducible factor (hif) hydroxylaseFIBROGEN INC·Filed 2021·Application pending·0 cites
- 4576US10765672B2Pharmaceutical formulations of a HIF hydroxylase inhibitorFIBROGEN INC·Filed 2018·Granted Sep 8, 2020·2 cites·6 claims
- 4676US6462063B1C-proteinase inhibitorsFIBROGEN INC·Filed 2000·Granted Oct 8, 2002·10 cites·28 claims
- 4776US6358741B1Connective tissue growth factor (CTGF) and methods of useFIBROGEN INC·Filed 1999·Granted Mar 19, 2002·40 cites·16 claims
- 4875US11229637B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2020·Granted Jan 25, 2022·0 cites·12 claims
- 4975US9034643B2Connective tissue growth factor antibodiesFIBROGEN INC·Filed 2012·Granted May 19, 2015·1 cites·12 claims
- 5075US6555322B1α2-macroglobulin receptor as a receptor for CTGFFIBROGEN INC·Filed 2000·Granted Apr 29, 2003·6 cites·7 claims
Showing the top 50 of 118 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when FIBROGEN INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →